Non-coding RNAs in gynecologic cancer

•There is an increasing number of miRNAs, lncRNAs, and circRNAs that display dysregulation in gynecologic cancers.•This review provided thorough information on the kinds of literature regarding the role of some non-coding RNAs in gynecological cancers.•The approach of using non-coding RNA in cancer diagnosis and treatment will elevate early diagnosis, prognosis, follow-up, and therapy. The term “gynecologic cancer” pertains to neoplasms impacting the reproductive tissues and organs of women encompassing the endometrium, vagina, cervix, uterus, vulva, and ovaries. The progression of gynecologic cancer is linked to various molecular mechanisms. Historically, cancer research primarily focused on protein-coding genes. However, recent years have unveiled the involvement of non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs (LncRNAs), and circular RNAs, in modulating cellular functions within gynecological cancer. Substantial evidence suggests that ncRNAs may wield a dual role in gynecological cancer, acting as either oncogenic or tumor-suppressive agents. Numerous clinical trials are presently investigating the roles of ncRNAs as biomarkers and therapeutic agents. These endeavors may introduce a fresh perspective on the diagnosis and treatment of gynecological cancer. In this overview, we highlight some of the ncRNAs associated with gynecological cancers.